TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04690881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychodrama group psychotherapy
Description: In order to reduce the fear of cihildbirth, pregnant women are given 90 minutes right after the training in addition to the routine pregnancy training. In the psychodrama-based pregnancy education program, fear of childbirth were assesment by sociometric measurement in order to increase the awareness of pregnant women about birth fear levels in the first week. Afterwards, they were given the opportunity to express themselves about the factors that may cause fear in pregnant women (their previous traumatic experiences, negative prejudices about childbirth, etc). The group members shared about their process in the first session and the session was ended. The session was evaluated with other researchers. In the following sessions, in order to strengthen their coping with the fear of childbirth, besides psychodrama warm-up games, the basic techniques of psychodrama, role switching, matching and mirror were used in protogonist works.
Study: NCT00977522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03463275
Description: 30 mg Controlled Release tablet BID for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet BID
Study: NCT03397056

Intervention type: OTHER
Intervention: Questionnaire
Description: The Questionnaire is provided in the links at the end of the declaration.
Study: NCT02849093

Intervention type: OTHER
Intervention: Non-invasive OCT imaging
Description: Optical Coherence Tomography (OCT) to capture high resolution cross-sectional images of tissue microstructures using infra-red radiation.

Intervention type: OTHER
Intervention: Non-invasive OCT imaging
Description: Optical Coherence Tomography (OCT) to capture high resolution cross-sectional images of tissue microstructures using infra-red radiation.

Intervention type: OTHER
Intervention: Non-invasive OCT imaging
Description: Optical Coherence Tomography (OCT) to capture high resolution cross-sectional images of tissue microstructures using infra-red radiation.
Study: NCT05099198

Intervention type: DRUG
Intervention: Sitagliptin
Description: Sitagliptin dispensing claim is used as the reference

Intervention type: DRUG
Intervention: Glimepiride
Description: Glimepiride dispensing claim is used as the reference
Study: NCT02995005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: 300 mg daily
Study: NCT01499628

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Reading
Description: Participant attends once a week for three weeks for a 45 minute appointment of supervised reading using appropriate spectacles and/or glasses

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVT at the PRL
Description: Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EVT at the TRL
Description: Participant attends once a week for three weeks for a 45 minute appointment of TRL training using the MAIA microperimeter and then further reading using magnifiers and/or spectacles.
Study: NCT02184026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure, Relaxation, & Rescripting Therapy-Child
Description: Exposure, Relaxation, \& Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing, child-friendly exposure to the trauma-nightmare, and rescription.
Study: NCT00858845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine Patch
Description: A clonidine patch (0.1 mg/week) to be worn for a period of 3 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Patch
Description: A matching placebo patch to be worn for a period of 3 months.
Study: NCT04383886

Intervention type: OTHER
Intervention: stress and anxiety questionnaire
Description: Emergency department staff will be asked to fill in questionnaires in order to measure their stress and anxiety level, their propensity to have a burn-out, their consumption of psychoactive substances such as alcohol, tobacco, coffee or anxiolytic, their sleep disorder.
Study: NCT03452319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pretraining
Description: Increased physical activity, and daily strength training and breathing exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Preoperative information
Study: NCT00367861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interruption of Glivec®
Description: interruption of Glivec®
Study: NCT01794039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT00622414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Given IV
Study: NCT02458586

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary intervention / counseling
Description: dietary counseling and daily intake of 50 g of dietary oil over a period of 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention / counseling
Description: dietary counseling and daily intake of 50 g of dietary oil over a period of 8 weeks
Study: NCT04411966

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-fluorothymidine
Description: Patients receive fluorothymidine F-18 IV over 1 minute and undergo PET scan over 60 minutes at least 10 days prior to systemic chemotherapy, and at least 10 days after first and second cycles of systemic chemotherapy.
Study: NCT03421834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation of ventricular tachycardia
Description: Catheter ablation with a uniform mapping system, procedural endpoint, and definition of acute procedural success.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optimal medical treatment
Description: Optimal guidelines-based heart failure treatment and antiarrhythmic drugs. Antiarrhythmics will be avoided if possible in the ablation group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimal medical treatment
Description: Optimal guidelines-based heart failure treatment and antiarrhythmic drugs. Antiarrhythmics will be avoided if possible in the ablation group.
Study: NCT00127946

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AMNIOECHANGE
Description: The AMNIOECHANGE consists of a transabdominal infusion of saline (heated to 37 ° C) with a needle 18 or 20 gauge under ultrasound monitoring while avoiding the placenta. In the case of a normal amniotic fluid, it must be replaced volume per volume of saline (eg depending on the tank where the puncture is made, it can be 300 per 300 ml). The total amount of amniotic fluid exchange is 600-900 ml. In cases of oligohydramnios, the AMNIOECHANGE results in a normalized volume of amniotic fluid.

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: AMNIOECHANGE
Description: The AMNIOECHANGE consists of a transabdominal infusion of saline (heated to 37 ° C) with a needle 18 or 20 gauge under ultrasound monitoring while avoiding the placenta. In the case of a normal amniotic fluid, it must be replaced volume per volume of saline (eg depending on the tank where the puncture is made, it can be 300 per 300 ml). The total amount of amniotic fluid exchange is 600-900 ml. In cases of oligohydramnios, the AMNIOECHANGE results in a normalized volume of amniotic fluid.
Study: NCT05497362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real tDCS
Description: 2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 15 minutes. Speech therapy was delivered simultaneously.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: 2mA of tDCS was delivered to the orofacial area of the primary motor cortex (SM1) for 30 sec. Speech therapy was delivered simultaneously.
Study: NCT05246462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Logotherapy
Description: In this study, the experimental group received seven-session logotherapy-based interviews on making sense of life, while the control group received only routine nursing care. In this study, Personal Meaning Oriented Psychotherapy (PMOP) was used to structure interviews on making sense of life based on Logotherapy and enhance the sense of meaning in cancer patients, share their concerns, experiences, and feelings about diagnosis-treatment, have their difficulties defined, maintain, and develop their sense of purpose and responsibility.
Study: NCT03744143

Intervention type: PROCEDURE
Group type: OTHER
Intervention: longitudinal suture
Description: Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a longitudinal suture

Intervention type: PROCEDURE
Group type: OTHER
Intervention: transverse suture
Description: Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a transverse suture

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Removal of vaginal endometriotic nodule
Description: Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, or vaginal technique, isolating the nodule through the vagina.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Removal of vaginal endometriotic nodule
Description: Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, or vaginal technique, isolating the nodule through the vagina.
Study: NCT03671590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1701
Description: Oral daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1701
Description: Oral daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1701
Description: Oral daily dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Oral Daily Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: IV infusion
Study: NCT04678206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-5937
Description: Oral administration of BLU-5937 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-5937
Description: Oral administration of BLU-5937 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-5937
Description: Oral administration of BLU-5937 Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-5937
Description: Oral administration of BLU-5937 Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of matching placebo for BLU-5937 Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of matching placebo for BLU-5937 Tablets
Study: NCT02258984

Intervention type: DEVICE
Group type: OTHER
Intervention: Mespere Venus 1000 Non-Invasive CVP System
Description: The Venus 1000 CVP System is a non-invasive central venous pressure measurement system that utilizes the proven science of NIRS. Approved by FDA, received Health Canada Medical Device Licence and CE Marked, the Venus 1000 has been proven to be clinically equivalent to measurements made via right heart catheterization.

Intervention type: DEVICE
Group type: OTHER
Intervention: Mespere Venus 1000 Non-Invasive CVP System
Description: The Venus 1000 CVP System is a non-invasive central venous pressure measurement system that utilizes the proven science of NIRS. Approved by FDA, received Health Canada Medical Device Licence and CE Marked, the Venus 1000 has been proven to be clinically equivalent to measurements made via right heart catheterization.
Study: NCT02166879

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Participants complete anesthesia questionnaire before elective surgical procedure.
Study: NCT05415657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60 mg per 6 month were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equal volume of saline (0.9%) as placebo Q6M were injected subcutaneously on the same day after lumbar fusion surgery, and all participants received calcium supplementation 1200 mg/D and vitamin D 800 IU/D.
Study: NCT04292951

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid and inotropic/vasoactive management protocol
Description: GDT protocol: keep SVV 10-13% and give fluid when SVV \> 13%, give inotropic to maintain CI 2.5-4 L/min/m2, give vasoactive drugs to maintain SVRI 1,900-2,400 dynes-sec/cm-5/m2 Control protocol: keep CVP 8-12 mmHG and give fluid when CVP \< 8 mmHg, give inotropic/vasoactive to maintain normal blood pressure and heart rate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid and inotropic/vasoactive management protocol
Description: GDT protocol: keep SVV 10-13% and give fluid when SVV \> 13%, give inotropic to maintain CI 2.5-4 L/min/m2, give vasoactive drugs to maintain SVRI 1,900-2,400 dynes-sec/cm-5/m2 Control protocol: keep CVP 8-12 mmHG and give fluid when CVP \< 8 mmHg, give inotropic/vasoactive to maintain normal blood pressure and heart rate
Study: NCT00697164

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Admission, day 1, day 2 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Erythropoietin, 1500 U/kg/day Admission, day 1, day 2 3 days
Study: NCT01858948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega
Description: Omega-3 supplements

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar in shape and color to Omega supplements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: Prior to randomization to Omega/placebo, patients were started on 100 mg BID of quetiapine, and the dose adjusted based on tolerability and response. The quetiapine target dose is 400-600 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Quetiapine fumarate
Description: Prior to randomization to Omega/placebo, patients were started on 100 mg BID of quetiapine, and the dose adjusted based on tolerability and response. The quetiapine target dose is 400-600 mg.
Study: NCT03415880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive workshops LiPAT intervention group
Description: Workshops include practical behavior change strategies and address barriers to movement, awareness of the immediate benefits of movement and implementation-intentions. Participants will be encouraged to cultivate a learning mind-set in order to better tolerate potential set-backs and to apply strategies such as pre-planning their week to incorporate physical activity, engaging their social network, and setting up systems and habits. Participants' progress in changing their physical activity patterns which will be compared and discussed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist-worn feedback physical activity monitor
Description: Participants receive the feedback monitor (Fitbit inspire®; commercially available consumer product (https://www.fitbit.com/inspire)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone application LiPAT
Description: With a cloud-based platform the iHealth data is synchronized with a mobile phone app developed by the research team. The app is designed to help the participant to self-monitor their physical activity levels and includes information on total activity and number of steps taken.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Coaching
Description: participants in the intervention group will receive telephone coaching during the first 3 months of the intervention. Telephone coaching will be conducted twice in the first month and once each in months two and three. The researcher will enquire about the progress with increasing LiPA, about the experiences of applying the strategies discussed during workshops, and about the experience with Fitbit Inspire® and the corresponding app. If needed, the coach will offer suggestions to improve goal adherence.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Workshops control group LiPAT
Description: During the first 6 months of the study (the intervention period) participants in the control group will attend 4 workshops in which the benefits of physical activity and the health-risks of sedentary behavior will be discussed. Additionally, information will be provided on healthy lifestyle for patients with type 2 diabetes.
Study: NCT00998946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: Pralatrexate injection administered as intravenous (IV) push

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1 mg intramuscular (IM) injection

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Oral 1 mg tablet
Study: NCT04227600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-171 (lepunafusp alfa)
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-171 (lepunafusp alfa)
Description: IV infusion
Study: NCT02693418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acidform 5 g
Description: Effect of 5 g vaginally administered Acidform on pH over 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 4 g
Description: Effect of 4 g of vaginally administered HEC placebo gel on pH over 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acidform 4 g
Description: Effect of 4 g vaginally administered Acidform on pH over 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acidform 3 g
Description: Effect of 3 g vaginally administered Acidform on pH over 7 days
Study: NCT01627717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (5 days)
Description: Subjects will receive maraviroc 150 mg tablets (1 tablet) every 12 hours from days 1 to 5 inclusively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc and boceprevir (14 days)
Description: From days 6 to 19, inclusively, boceprevir 800 mg (4 capsules of 200 mg) every 8 hours with food will be given with maraviroc 150 mg (1 tablet of 150 mg) every 12 hours.
Study: NCT03284554

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Encapsulated nutrients
Description: Amino acid + Lipid; Probiotic bacteria

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Non-encapsulated nutrients
Description: Amino acid + Lipid; Probiotic bacteria

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nutrient not expected to stimulate release of GLP-1 and PYY
Study: NCT03564262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Sodium Meal (138 mg sodium)
Description: One Low Sodium Meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Sodium Meal (138 mg sodium)
Description: One Low Sodium Meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Sodium Meal (1,495 mg sodium)
Description: One High Sodium Meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Sodium Meal (1,495 mg sodium)
Description: One High Sodium Meal
Study: NCT01228045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab in Combination with TS-ONE and cisplatin
Description: Subjects will receive treatment that combined TS-ONE, cisplatin and trastuzumab every 3 weeks in this study. This 3 weeks period of time is called a cycle. The cycle will be repeated until subject experience disease progression or unbearable toxicities or they choose to withdraw from the study. Each cycle is numbered in order.
Study: NCT01905072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Home Visits
Description: Intervention will include educational home visits on:~1. Growth monitoring and feedback~2. Feeding: support exclusive breastfeeding until 6 months; delay solid feeding until 6 months; appropriate amounts of food for age; stop bottle feeding at 12 months; have nothing but breast milk/formula/4 oz juice in bottle; limit juice amount to 4 oz day; introduce cup by 10-11 months; no sweetened beverages; limited amounts of sweets.~3. Parenting: recognizing hunger and satiety cues; handling colic/crying; engaging baby in play.~4. Activity: being active with the baby; no screen time for baby and limited to 1 hour for 1-3 year olds; promote active play while maintaining safety.~5. Sleep: at least 10-12 hours sleep per day needed; how to promote sleeping environment for baby.
Study: NCT00095966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT01966510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cord Blood Transplantation